TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00772473

Intervention type: OTHER
Intervention: subjects personal triptan
Description: Subjects will treat 1 migraine attack with their usual triptan
Study: NCT03835104

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRP point-of-care testing
Description: CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
Study: NCT02361749

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal Myectomy
Description: Longitudinal anal myectomy will be performed under general anesthesia as a day case.
Study: NCT02597842

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Description: Electric stimulation was given through electrode attached to specific acupoints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Description: Electric stimulation was given through electrode attached to specific acupoints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Description: Electric stimulation was given through electrode attached to specific acupoints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Description: Electric stimulation was given through electrode attached to specific acupoints
Study: NCT03338387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Acipimox

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Other Names: Placebo (for Olbetam)
Study: NCT03909763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine plus danazol
Description: Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks
Study: NCT00520676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2, IV, q 21 days x 6 cycles maximum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m\^2, IV, q 21 days x 6 cycles maximum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum
Study: NCT01011920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
Study: NCT03835104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP point-of-care testing
Description: CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
Study: NCT01011920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 conventional infusion on day - 5 \& 0 every 3 weeks for a maximum of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 conventional infusion on day - 5 \& 0 every 3 weeks for a maximum of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 \& -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 \& -4

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APBSCT
Description: Autologous peripheral blood stem cell transplant (APBSCT)
Study: NCT06673719

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-pertechnetate SPECT/CT
Description: This procedure is similar to standard Meckel's diverticulum scan, with the addition of SPECT/CT acquisition to measure gastric volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined High-Resolution Manometry-Nutrient Drink Test
Description: Proximal gastric high-resolution manometry was done concurrently with nutrient drink test to measure proximal gastric function.
Study: NCT02940522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Study: NCT04439279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study: NCT03598829

Intervention type: DIAGNOSTIC_TEST
Intervention: Tryptase, Serum test
Description: Blood draw lab test which measures concentration of Tryptase in the sample. Tryptase is the one of the primary secretions of active mast cells and is used as a measure of inflammatory activity. Normal Reference Value: \&lt;11.5 ng/mL
Study: NCT00997061

Intervention type: DRUG
Intervention: HYCAMTIN
Description: Observing patients on HYCAMTIN and other drugs for SCLC.
Study: NCT06624345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Patients in the IMT group received the intervention using a threshold loading device set at a pressure range of 5-39 cmH₂O. They were instructed to perform six sets of five breaths, totaling 30 breaths, twice daily for six weeks. Additionally, the aerobic exercise regimen included upper limb exercises (raising arms without resistance), a lower limb stepping warm-up, and a walking routine consisting of 5 minutes of slow walking, 2 minutes of brisk walking, and another 5 minutes of slow walking, for a total of 30 minutes per day.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Subjects received routine care.
Study: NCT04178005

Intervention type: DRUG
Group type: OTHER
Intervention: Cladribine
Description: All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI
Study: NCT04581577

Intervention type: OTHER
Intervention: Semi-structured telephone questionnaire
Description: Semi-structured telephone questionnaire

Intervention type: OTHER
Intervention: Semi-structured telephone questionnaire
Description: Semi-structured telephone questionnaire
Study: NCT04066504

Intervention type: DRUG
Intervention: sonidegib
Description: Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)
Study: NCT02940522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Study: NCT01763658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antox tablets(Mepaco)
Description: effect of antioxidant on disease outcome

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drug therapy for ITP
Description: drugs will be selected according to ASH,2011 guidelines

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: drug therapy for ITP
Description: drugs will be selected according to ASH,2011 guidelines
Study: NCT03935737

Intervention type: DIAGNOSTIC_TEST
Intervention: Full Dose Chest X-Ray
Description: Full dose X ray at Day 1

Intervention type: DIAGNOSTIC_TEST
Intervention: Low Dose Chest X-Ray
Description: Low dose X ray within 3 months from full dose
Study: NCT05341934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluative Conditionning Task
Description: A word will appear in one of the four quadrants on the computer screen. They will have to answer the word as quickly as possible by pressing the space bar. They will also be told that an image will be displayed briefly (400 ms) in the same quadrant by pressing the answer key. This procedure will be repeated for 120 trials: 30 trials with alcohol-related Conditional Stimulus (CS), 30 trials with CS related to non-alcoholic beverages and 60 trials with the CS of filling. The CS referring to alcohol will be the words Beer, Wine ...; The CS referring to soft drinks will be the words Coca-Cola, Fanta... and Filling CS referring to vegetables and fruits will be: Apple, Banana...In experimental conditions, alcohol-related CS will be followed by negative Unconditional Stimuli (US) (images from the International Affective Picture System (Lang, Bradley, \& Cuthbert, 1997)), CS referring to soft drinks linked to positive images and CS referring to fruits and vegetables will be linked to neutral US.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Evaluative Conditionning Task
Description: A word will appear in one of the four quadrants on the computer screen. They will have to answer the word as quickly as possible by pressing the space bar. They will also be told that an image will be displayed briefly (400 ms) in the same quadrant by pressing the answer key. This procedure will be repeated for 120 trials: 30 trials with alcohol-related Conditional Stimulus (CS), 30 trials with CS related to non-alcoholic beverages and 60 trials with the CS of filling. The CS referring to alcohol will be the words Beer, Wine ...; The CS referring to soft drinks will be the words Coca-Cola, Fanta... and Filling CS referring to vegetables and fruits will be: Apple, Banana...In experimental conditions, alcohol-related CS will be followed by negative Unconditional Stimuli (US) (images from the International Affective Picture System (Lang, Bradley, \& Cuthbert, 1997)), CS referring to soft drinks linked to positive images and CS referring to fruits and vegetables will be linked to neutral US.
Study: NCT03566511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
Study: NCT03033134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BSJ003W
Description: BSJ003W implant
Study: NCT03566511

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
Study: NCT00654641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound closure
Description: Applying negative pressure to primary wound closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound closure
Description: Standard wound closure
Study: NCT02257437

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LNS snack
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS snack
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LNS snack
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LNS snack
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn-soy blend ++ (CSB++)
Description: Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn-soy blend ++ (CSB++)
Description: Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn-soy blend ++ (CSB++)
Description: Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn-soy blend ++ (CSB++)
Description: Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sprinkles
Description: Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles
Description: Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sprinkles
Description: Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sprinkles
Description: Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
Study: NCT02723994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia Chrysanthemi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study: NCT02257437

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LNS + borbor
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
Study: NCT02723994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Study: NCT03631693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simplified papilla preservation flap
Description: The simplified papilla preservation flap (SPPF) surgery is a conservative surgical procedure aimed at the preservation of the tissues between the teeth providing access for the debridement of the root surface in sites with residual pockets.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resective periodontal flap with osseous recontouring
Description: The Resective periodontal flap with osseous recontouring (RPFO) is a surgical procedure that achieves predictable pocket depth reduction by soft and hard tissue resection to obtain a more convenient soft and hard tissue architecture for oral hygiene.
Study: NCT04187404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EO2401
Description: Multiple dose of EO2401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EO2401
Description: Multiple dose of EO2401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EO2401
Description: Multiple dose of EO2401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Multiple dose of nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Multiple dose of nivolumab
Study: NCT03306810

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AG service
Description: The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
Study: NCT04187404

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Multiple dose of nivolumab
Study: NCT04066829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default setting intervention
Description: The new default settings will be implemented only for patients in the experimental arm.
Study: NCT03995472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1501
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1501
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1501
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: Administered intravenously
Study: NCT02806973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.
Study: NCT00775671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
Study: NCT02257437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS + borbor
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LNS + borbor
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LNS + borbor
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
Study: NCT00775671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5 mg by mouth daily for 12 weeks.
Study: NCT01878773

Intervention type: OTHER
Group type: OTHER
Intervention: High Quality Volume CT Scan; MRI Scan
Description: Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.~--------------------------------------------------------------------------------
Study: NCT00775671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol ER 100mg by mouth daily for 12 weeks.
Study: NCT03552445

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus-diphtheria (Td) and PCV13
Description: 154 concomitant Td-PCV13 recipients: one dose of each vaccine administered on Day 0
Study: NCT02806973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.
Study: NCT03552445

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13 alone
Description: 154 PCV13 recipients: one vaccine injection administered on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td alone
Description: 437 Td recipients: one vaccine injection administered on Day 0
Study: NCT02068456

Intervention type: DRUG
Intervention: Roflumilast
Study: NCT04473833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Transvaginal Ultrasonography
Description: Participants will undergo transvaginal ultrasonography (TVS) to detect ovarian cancer as part of the Kentucky Ovarian Cancer Screening Program. Those with normal findings will repeat the TVS in one year. Those with abnormal results will repeat the screening in 4-6 weeks.
Study: NCT04073368

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AXA1957
Description: Amino acids, food study
Study: NCT02769741

Intervention type: OTHER
Group type: OTHER
Intervention: Cashews followed by Control
Description: Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.

Intervention type: OTHER
Group type: OTHER
Intervention: Control followed by Cashews
Description: Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.